Videos

Expert Joyce O’Shaughnessy, MD, reviews data from the TROPiCS-02 study of sacituzumab govitecan in HR+/HER2- metastatic breast cancer.

Expert perspectives on a second patient case of unmutated metastatic breast cancer and available treatment strategies in this setting.

Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.

Antonio Ucar, MD, explains the rationale behind the phase 3 Peak study of bezuclastinib plus sunitinib in patients with gastrointestinal stromal tumors being treated in the second-line setting.

Robert J. Motzer, MD, provides insights on factors that influence treatment decisions for patients with clear cell renal cell carcinoma.

Continuing discussion on advanced renal cell carcinoma, Robert J. Motzer, MD, reviews recent clinical trial data presented at ASCO 2023 and KCRS 2023.

Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.

Ann LaCasce, MD, MMSc, discusses the effects that chemotherapy drug shortages may have on clinical trials and patient accrual.

Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, share key takeaways from their program with Jonathan Friedberg, MD, MMSc, on practice-changing data from the POLARIX and SWOG S1826 clinical trials.

Switching their focus to the SWOG S1826 clinical trial in Hodgkin’s Lymphoma, Rohit Gosain, MD, Rahul Gosain, MD, and Jonathan Friedberg, MD, MMSc, consider the role of frontline R-AVD versus BV-AVD.

Following their discussion on the phase 3 POLARIX trial in DLBCL, Jonathan Friedberg, MD, MMSc, and the Oncology Brothers consider how frontline polatuzumab vedotin will be used in the real-world setting.

Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by expert Jonathan Friedberg, MD, MMSc, to review data with frontline polatuzumab vedotin in DLBCL from the phase 3 POLARIX trial.

The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.

Clinical experiences with belusmosudil are shared among the panel.

Chad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.

Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.

A focused review of data from the EMERALD study, which tested elacestrant, an oral SERD, in patients with HR+/HER2- metastatic breast cancer.

Jonathan C. Trent, MD, PhD, discusses why it is necessary for patients with gastrointestinal stromal tumors to have comprehensive testing to find actionable genomic alterations.

The results of a phase 1b trial looking at the use of acalabrutinib for patients with treatment-naive or relapsed/refractory mantle cell lymphoma has provided the support needed for the phase 3 ECHO study of this treatment.

An expert medical oncologist reviews recent data updates on lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, provides an overview of the CLEAR trial investigating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.

Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.

A review of fam-trastuzumab deruxtecan nxki shows how it has become a standard of care for patients with metastatic breast cancer that is HER2-positive.

In light of the second-line treatment armamentarium for patients with HR+/HER2- metastatic breast cancer, expert oncologists discuss the selection and sequencing of specific agents in this setting.

Joyce O’Shaughnessy, MD, highlights key data from a number of clinical trials in the second-line treatment setting of HR+/HER2- metastatic breast cancer.

Barbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.